Norway
Key Insights
- 1
No psychedelic therapy is approved in Norway; ketamine and esketamine may be used clinically, but psilocybin, MDMA and similar drugs remain illegal outside research.
- 2
Blossom counts 5 Norway trials, 0 active; the pipeline is concentrated in esketamine, ketamine, MDMA and placebo across just 3 research organisations.
- 3
Norway’s standout marker is its strict narcotics regime: possession, use and sale remain criminal offences, making it a conservative European comparator.
- 4
Momentum is centred on Oslo University Hospital and UiB-linked translational psychiatry teams, with fresh neuropsychiatric infrastructure and funding keeping the field alive.
Reimbursed Care Access
Norway maintains a broadly prohibitive criminal/drug-scheduling regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, 2C‑series, ibogaine, ayahuasca), while ketamine-based treatments have an evolving medical pathway: esketamine (Spravato) has not been adopted into public reimbursement, whereas off‑label intravenous racemic ketamine has been authorized for use within specialist services and publicly reimbursed for treatment‑resistant depression under strict conditions as of August 25, 2025. Access to other psychedelics is effectively limited to approved clinical research or is entirely prohibited outside of statutory exceptions.
Quick Indicators
Research Events
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Norway.